Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03267888 · OUTCOME

Number of Participants Who Showed an Overall Response to Treatment Based on Baseline Changes on Positron Emission to Positron Emission Tomography/Computed Tomography

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2024-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
95% Confidence Interval
Time frame
Up to 12 months after study start

What was measured

Will be defined using International IMWG criteria.

Groups in this outcome

Radiation Therapy, Pembrolizumab

Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Pembrolizumab: Given 200 mg/kg IV. Radiation Therapy: Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Radiation Therapy, Pembrolizumab25

Reported measurements

Source class 1
Values in participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Radiation Therapy, Pembrolizumab20Not reported741Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        7
        upper Limit
        41
        value
        20
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Will be defined using International IMWG criteria.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Pembrolizumab: Given 200 mg/kg IV. Radiation Therapy: Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
    id
    OG000
    title
    Radiation Therapy, Pembrolizumab
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 12 months after study start
title
Number of Participants Who Showed an Overall Response to Treatment Based on Baseline Changes on Positron Emission to Positron Emission Tomography/Computed Tomography
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice